Diagnostic utility of IGF-1/IGFBP-3 ratio and the insulin tolerance test in diagnosing growth hormone deficiency.
文献摘要
Purpose Diagnosing Growth Hormone Deficiency (GHD) is challenging due to pulsatile GH secretion and high false-positive rates in traditional stimulation tests. This study evaluates the diagnostic utility of the IGF-1/IGFBP-3 molar ratio as a complementary tool to the gold-standard Insulin Tolerance Test (ITT). Methods A retrospective study analyzed 225 pediatric patients (aged 2-18) evaluated for short stature between 2015 and 2025. Confirmed GHD required a peak GH Results The cohort included 82 GHD and 143 non-GHD subjects. The mean IGF-1/IGFBP-3 molar ratio SDS was significantly lower in the GHD group compared to non-GHD (-1.6 ± 1.1) vs (-1.1 ± 1.1). Integrating the molar ratio SDS with ITT significantly enhanced diagnostic specificity. A threshold of Conclusion Stratifying the ITT with the IGF-1/IGFBP-3 molar ratio mitigates GHD over-diagnosis. The < -2 SDS threshold's high specificity ensures hormone replacement therapy is accurately targeted, advancing precision medicine for pediatric growth disorders.